Episode 69. ASH 2025 Lymphoma Roundup with Dr. Carla Casulo
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Episode 69. ASH 2025 Lymphoma Roundup with Dr. Carla Casulo
-
Narrado por:
-
De:
BloodCancerTalks: ASH 2025 Lymphoma Roundup
Guest: Dr. Carla Casulo, Associate Professor, Wilmot Cancer Centre, University of Rochester
Abstracts Discussed
Follicular Lymphoma
EPCORE-FL1 (Falchi) - Epcoritamab plus lenalidomide-rituximab (R2) in relapsed/refractory FL
Theme: Bispecific antibody combinations in R/R FL; comparing to other approaches
Diffuse Large B-Cell Lymphoma (DLBCL) - Elderly/Unfit Patients
MorningSun (Sharman) - Mosunetuzumab monotherapy in patients ≥80 years or chemo-ineligible
EPCOR-DLBCL-3 (Vitolo) - Epcoritamab monotherapy in elderly patients
R-Pola-Glo - Rituximab-polatuzumab-glofitamab combination in older/frail patients
Theme: Single-agent and combination bispecific strategies for elderly and frail DLBCL patients
DLBCL - First-Line Treatment
SMART STOP (Westin) - Chemotherapy-free approach using lenalidomide, tafasitamab, rituximab, acalabrutinib (ULTRA regimen)
FrontMIND - Tafasitamab-lenalidomide added to R-CHOP
Theme: Chemotherapy-sparing and chemo-intensification strategies in newly diagnosed DLBCL
DLBCL - Relapsed/Refractory
DALY 2-EU (Borchmann) - Dual CD19/CD20 CAR-T (zamto-cel) versus R-GemOx in transplant-ineligible patients
Theme: Expanding CAR-T eligibility; treatment selection in transplant-ineligible R/R DLBCL
Hodgkin Lymphoma
SWOG 1826 - 3-year update: Nivolumab-AVD versus brentuximab-AVD
HD21 - 5-year update: PET-adapted BrECADD versus BEACOPP
Theme: Long-term outcomes and treatment selection in newly diagnosed Hodgkin lymphoma
Burkitt Lymphoma
ZUMA-25 (Van Dorp) - Brexucabtagene autoleucel (Brexu-cel) in relapsed/refractory Burkitt
Theme: CAR-T therapy for the challenging population of R/R Burkitt lymphoma
Mantle Cell Lymphoma - First-Line
TrAVeRse - Acalabrutinib, venetoclax, rituximab
GLOVe - Glofitamab, lenalidomide, venetoclax (high-risk MCL)
BOVen - Zanubrutinib, obinutuzumab, venetoclax (older patients)
MAVO - Acalabrutinib, venetoclax, obinutuzumab
Window-3 - Acalabrutinib-rituximab followed by brexu-cel (high-risk MCL)
Theme: Chemotherapy-free combinations in newly diagnosed mantle cell lymphoma